Efficacy and safety of a soy isoflavone extract in postmenopausal women: A randomized, double-blind, and placebo-controlled study

Nahás, Eliana Aguiar Petri; Orsatti, Fábio Lera; Carvalho, Eduardo Pessoa; Oliveira, Maria Luiza Cotrim Sartor de; Dias, Rogério

doi:10.1016/j.maturitas.2007.08.012

Cited by 87 publications

(84 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They suggest that exposure to certain isoflavones may modulate pathway of estrogen catabolism (Wood et al, 2007). Nahas et al (2007) showed that regular consumption of soy isoflavone extract (100 mg) produces a significantly higher reduction in the number of hot flushes than placebo. Chiechi et al (2003) reported that dietary phytoestrogens may modulate the consequences of the postmenopausal estrogen deficiency state (Chiechi et al, 2002b).…”

Section: Discussionmentioning

confidence: 99%

Can Soy Change Serum Estradiol Concentration in Neonate Ovariectomized Rat?

N.¹

2012

American Medical Journal

View full text Add to dashboard Cite

Problem statement: Phytoestrogens are plant derived compound found in a wide variety of foods, most notably soy. The purpose of this study was to assess the effect of soy isoflavones on circulating 17-β estradiol in neonate ovariectomized rat. Approach: Thirty, one day olds rats were used. Blood sample were collected after two months. 17-β estradiol was assayed by radioimmuno assay method. Data were analyzed by one way ANOVA and Duncan as post-hoc test. The level of significance was considered p<0.05. Results: Our data showed that ovariectomy significantly (p<0.05) reduced serum 17-β estradiol. Application of soy in doses 0.75 and 1.5 mL kg −1 day −1 following ovariectomy had not significant effect relative to ovariectomy without application of soy, but application of soy in dose 3 mL kg −1 day −1 significantly (p<0.05) increased 17-β estradiol relative to ovariectomy without application of soy. There was no significant difference between dose 3 mL kgday −1 and control and sham group. Conclusion/Recommendation: Our results indicated that soy milk isoflavone can compensate the 17-β estradiol decrease in ovariectomized rat.

show abstract

Section: Discussionmentioning

confidence: 99%

Can Soy Change Serum Estradiol Concentration in Neonate Ovariectomized Rat?

N.¹

2012

American Medical Journal

View full text Add to dashboard Cite

show abstract

“…W niektórych przypadkach, w których stosowanie preparatów hormonalnych jest niemożliwe z powodu występowania przeciwwskazań lub odmowy pacjentki, można zastosować leki roślinne, których podstawowym składnikiem są fitoestrogeny. Zastosowanie fitoestrogenów w terapii wieku okołomenopauzalnego może stanowić formę terapii pierwszego rzutu u kobiet z łagodnie wyrażanymi objawami wypadowymi oraz u pacjentek po 65. roku życia [14].…”

Section: Leczenie Objawów Zespołu Klimakterycznegounclassified

The role of physical activity in menopause

Dąbrowska¹,

Naworska²,

Dąbrowska-Galas³

et al. 2012

View full text Add to dashboard Cite

StreszczenieOkres klimakteryczny to czas, w którym kobiety doświadczają nieprzyjemnych objawów wypadowych o róż-nym nasileniu. Szacuje się, że ok. 85-89% kobiet deklaruje odczuwanie nieprzyjemnych objawów klimakterycznych będących wynikiem zmian hormonalnych, co pogarsza ich komfort życia i sprawia, że ten okres staje się szczególnie trudny. Istotnym modyfikacjom ulegają zachowania seksualne dotyczące zmiany libido, obniżenia zainteresowania seksem oraz pożądania seksualnego, co w połączeniu z suchością pochwy często powoduje dyskomfort podczas stosunków płciowych. Mimo poglądu że aktywność seksualna zmniejsza się w okresie około-menopauzalnym wraz z zanikiem produkcji estrogenów, wyniki badań zaprzeczają tej tezie. Wybór metody terapii zaburzeń seksualnych kobiet w okresie okołomenopauzalnym powinien uwzględnić etiopatogenezę i stopień nasilenia dysfunkcji, a ryzyko występowania działań niepożądanych, wynikających ze stosowanej terapii, nigdy nie powinno przewyższać płynących z niej korzyści. Indywidualnie dobrana terapia hormonalna (menopausal hormone therapy -MHT) stanowi powszechnie stosowaną metodę łagodzenia objawów menopauzalnych. Naturalne metody bazujące na zmianie stylu życiu, regularnej aktywności fizycznej i racjonalnej diecie są alternatywą dla kobiet w łagodzeniu dyskomfortu związanego z okresem okołomenopauzalnym. Aktywność fizyczna stanowi bardzo istotny element zdrowego trybu życia, wpływający bezpośrednio lub pośrednio na inne nawyki. Promocja zdrowego stylu życia jest szczególnie ważna w uświadomieniu pacjentkom konieczności zadbania o zdrowie, zrezygnowania z nałogów, wdrożenia w życie codzienne regularnej aktywności fizycznej i zdrowego żywienia.Słowa kluczowe: menopauza, jakość życia, aktywność fizyczna. SummaryThe climacteric period is a time when women experience many unpleasant symptoms with different intensity. It has been reported that 85-89% of women experience climacteric symptoms resulting from hormonal fluctuations, which affect their quality of life, therefore this time can be difficult for women. During menopause sexual behaviours are modified because of low libido, decreased interest in sex and sexual desire, and vaginal dryness which cause discomfort during sexual intercourses. Despite the opinion about a decrease in sexual activity caused by a low level of estrogen during menopause, the results of different studies contradict this thesis. Etiopathogenesis and the intensity of sexual dysfunctions should be considered before choosing treatment in menopausal women, and undesirable effects of the therapy should never exceed its benefits. Individually tailored menopausal hormone therapy (MHT) is commonly used to ease menopausal symptoms in women with moderate or severe intensity of these symptoms. Natural methods such as making positive lifestyle changes, regular physical activity and healthy diet represent an alternative for menopausal women suffering from some climacteric syndromes. Physical activity is one of the major lifestylerelated determinant which directly or indirectly in...

show abstract

“…Ten RCTs investigated the effect of soy isoflavones on both frequency and severity of hot flushes (Albertazzi et al, 2005;Cheng et al, 2007;D'Anna et al, 2009;Evans et al, 2011;Khaodhiar et al, 2008;Knight et al, 2001;Lopes de Sousa et al, 2006;Nahas et al, 2007;St Germain et al, 2001;Upmalis et al, 2000), three investigated frequency only (Crisafulli et al, 2004;Faure et al, 2002;Ferrari, 2009) and two severity only (Han et al, 2002;Kotsopoulos et al, 2000). Three of these studies also investigated the effect of soy isoflavones on night sweats (Cheng et al, 2007;St Germain et al, 2001;Upmalis et al, 2000).…”

Section: Reduction Of Vasomotor Symptoms Associated With Menopause (Imentioning

confidence: 99%

“…Five (Crisafulli et al, 2004;D'Anna et al, 2009;Evans et al, 2011;Ferrari, 2009;Nahas et al, 2007) of the 13 RCTs which investigated the effect of soy isoflavones on frequency of hot flushes reported a statistically significant effect of soy isoflavones on this outcome. These five studies together considered 575 subjects for data analysis (30-119 subjects per group) and provided 27 to 100 mg soy isoflavones per day for 3-24 months.…”

Section: Reduction Of Vasomotor Symptoms Associated With Menopause (Imentioning

confidence: 99%

Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessmen

Products¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 in the framework of further assessment related to soy isoflavones and maintenance of bone mineral density and reduction of vasomotor symptoms associated with menopause. The food constituent that is the subject of the claim, soy isoflavones, is sufficiently characterised. The claimed effects, maintenance of bone mineral density and reduction of vasomotor symptoms associated with menopause, which are eligible for further assessment, are beneficial physiological effects. The proposed target populations are peri‐ and/or post‐menopausal women. On the basis of the data presented, the Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of soy isoflavones and maintenance of bone mineral density, and between the consumption of soy isoflavones and reduction of vasomotor symptoms associated with menopause.

show abstract

Efficacy and safety of a soy isoflavone extract in postmenopausal women: A randomized, double-blind, and placebo-controlled study

Cited by 87 publications

References 39 publications

Can Soy Change Serum Estradiol Concentration in Neonate Ovariectomized Rat?

Can Soy Change Serum Estradiol Concentration in Neonate Ovariectomized Rat?

The role of physical activity in menopause

Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessmen

Contact Info

Product

Resources

About